Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
29.90
+0.54 (1.86%)
At close: May 27, 2025, 4:00 PM
29.90
0.00 (0.02%)
After-hours: May 27, 2025, 4:28 PM EDT
Alkermes Employees
Alkermes had 1,800 employees as of December 31, 2024. The number of employees decreased by 300 or -14.29% compared to the previous year.
Employees
1,800
Change (1Y)
-300
Growth (1Y)
-14.29%
Revenue / Employee
$840,983
Profits / Employee
$195,948
Market Cap
4.93B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ALKS News
- 26 days ago - Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible - Seeking Alpha
- 26 days ago - Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Alkermes plc Reports First Quarter 2025 Financial Results - PRNewsWire
- 27 days ago - New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) - PRNewsWire
- 5 weeks ago - Alkermes to Report First Quarter Financial Results on May 1, 2025 - PRNewsWire
- 7 weeks ago - Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 2 months ago - Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PRNewsWire
- 2 months ago - New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PRNewsWire